Protected: Opperman
influence
Pfizer’s efforts to block Colombia’s accession to the OECD in 2017-2018
The following PDF file includes several email exchanges between Pfizer and USTR regarding Colombia’s accession to the Organisation for Economic Co-operation and Development (OECD). Pfizer proposed several conditions it wanted Colombia to agree to before the US would withdraw objections… Continue Reading
Noncommunicable disease partnerships and conflicts of interest
KEI was invited to participate in the “WHO Global Dialogue on Partnerships for Sustainable Financing of Noncommunicable Disease (NCD) Prevention and Control,” which was held in Copenhagen, Denmark, April 9-11, 2018. A web page for the event is here. Overall,… Continue Reading
People who oppose robust copyright exceptions for blind people (the Private Sector)
May 18, 2013 About the list. This is a work in progress. KEI has been engaged in the negotiations for a WIPO treaty on copyright exceptions for persons with disabilities since 2008. We have attended each negotiation that has been… Continue Reading
Jeffrey Kindler rewarded by Pfizer for his influence with governments
On July 28, 2006, Jeffrey Kindler replaced Hank McKinnell as CEO of Pfizer. That day the Pfizer stock price closed at $26.11. With the stock trading today at a little more than $17, it would seem that shareholders have lost a significant amount of their investment. Nonetheless, Kindler is doing well.